Press release
H3N2 Infection Pipeline Appears Robust With 15+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight
Explore our latest breakthroughs in H3N2 Infection Research. Learn more about our innovative pipeline today! @ H3N2 Infection Pipeline Outlook [https://www.delveinsight.com/sample-request/h3n2-infection-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Key Takeaways from the H3N2 Infection Pipeline Report
* In July 2025, Seqirus announced a Phase 3 study is a randomized, observer-blind study of MF59-adjuvanted influenza vaccine (aQIV or aTIV) compared with a non-adjuvanted influenza vaccine (QIV or TIV) in adults greater than or equal to 65 years of age. The aim of the study is to evaluate MF59-adjuvanted influenza vaccine compared with non-adjuvanted influenza vaccine in the prevention of reverse transcription-polymerase chain reaction (RT-PCR)-confirmed influenza A and/or B in subjects greater than or equal to 65 years of age.
* DelveInsight's H3N2 Infection pipeline report depicts a robust space with 15+ active players working to develop 20+ pipeline therapies for H3N2 Infection treatment.
* The leading H3N2 Infection Companies such as Novartis Vaccines, PDS Biotechnology Corporation, Sanofi, Moderna Therapeutics, Pfizer, Cidara Therapeutics, GRDG Sciences, FluGen Inc., Barinthus Biotherapeutics and others.
* Promising H3N2 Infection Pipeline Therapies such as H3N2 (A/Belgium/2417/2015), Saline, MVA-NP+M1, PrEP-001 and others.
Stay informed about the cutting-edge advancements in H3N2 Infection treatments. Download for updates and be a part of the revolution in Infectious Disease Care @ H3N2 Infection Clinical Trials Assessment [https://www.delveinsight.com/sample-request/h3n2-infection-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
H3N2 Infection Emerging Drugs Profile
* mRNA-1083: Moderna Therapeutics
mRNA-1083 is under development for the prevention of influenza virus infection caused by influenza A/H1N1, A/H3N2, and influenza B/Yamagata and B/Victoria strains and coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), in 18 to 79 years of age group. It is a combination vaccine of mRNA-1283, which encodes Receptor Binding Doman (RBD) and N-Terminal Domain (NTD) of the spike protein and mRNA-1010, which encodes hemagglutinin (HA) glycoproteins of influenza A/H1N1, A/H3N2, and influenza B/Yamagata and B/Victoria-lineages. It is administered through intramuscular route in the form of sterile liquid for injection. Currently, the drug is in Phase III stage of its clinical trial for the treatment H3N2 infection.
* CD-388: Cidara therapeutics
CD-388 is under development of the treatment and prevention of influenza virus A, seasonal influenza, pandemic influenza and influenza virus B infections. The drug candidate is a second generation, anti-viral Fc conjugate (AVC). It comprises of two moieties attached through a chemical linker. One is a targeting moiety (TM) that recognizes cell surface target and another is an effector moiety (EM) that is recognized by the immune system. It is administered through intramuscular and subcutaneous route. Currently, the drug is in Phase II stage of its clinical trial for the treatment of H3N2 infection.
* PF-07845104: Pfizer
PF-07845104 is a prophylactic saRNA Vaccine developed by Pfizer. Its therapeutics area include infectious respiratory diseases. Currently, the drug is in phase I stage of its clinical trial for the treatment of H3N2 infection.
The H3N2 Infection Pipeline Report provides insights into
* The report provides detailed insights about companies that are developing therapies for the treatment of H3N2 Infection with aggregate therapies developed by each company for the same.
* It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for H3N2 Infection Treatment.
* H3N2 Infection Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
* H3N2 Infection Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
* Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the H3N2 Infection market.
Learn more about H3N2 Infection Drugs opportunities in our groundbreaking H3N2 Infection research and development projects @ H3N2 Infection Unmet Needs [https://www.delveinsight.com/sample-request/h3n2-infection-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
H3N2 Infection Companies
Novartis Vaccines, PDS Biotechnology Corporation, Sanofi, Moderna Therapeutics, Pfizer, Cidara Therapeutics, GRDG Sciences, FluGen Inc., Barinthus Biotherapeutics and others.
H3N2 Infection pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
* Intravenous
* Subcutaneous
* Oral
* Intramuscular
H3N2 Infection Products have been categorized under various Molecule types such as
* Monoclonal antibody
* Small molecule
* Peptide
Discover the latest advancements in H3N2 Infection treatment by visiting our website. Stay informed about how we're transforming the future of Infectious Disease @ H3N2 Infection Market Drivers and Barriers, and Future Perspectives [https://www.delveinsight.com/sample-request/h3n2-infection-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Scope of the H3N2 Infection Pipeline Report
* Coverage- Global
* H3N2 Infection Companies- Novartis Vaccines, PDS Biotechnology Corporation, Sanofi, Moderna Therapeutics, Pfizer, Cidara Therapeutics, GRDG Sciences, FluGen Inc., Barinthus Biotherapeutics and others.
* H3N2 Infection Pipeline Therapies- H3N2 (A/Belgium/2417/2015), Saline, MVA-NP+M1, PrEP-001 and others.
* H3N2 Infection Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* H3N2 Infection Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
For a detailed overview of our latest research findings and future plans, read the full details of H3N2 Infection Pipeline on our website @ H3N2 Infection Emerging Drugs and Companies [https://www.delveinsight.com/sample-request/h3n2-infection-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Table of Contents
* Introduction
* Executive Summary
* H3N2 infection: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* H3N2 infection- DelveInsight's Analytical Perspective
* Late Stage Products (Phase III)
* mRNA-1083: Moderna Therapeutics
* Drug profiles in the detailed report.....
* Mid Stage Products (Phase II)
* CD-388: Cidara therapeutics
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I)
* PF-07845104: Pfizer
* Drug profiles in the detailed report.....
* Preclinical and Discovery Stage Products
* Drug name: Company name
* Drug profiles in the detailed report.....
* Inactive Products
* H3N2 infection Key Companies
* H3N2 infection Key Products
* H3N2 infection- Unmet Needs
* H3N2 infection- Market Drivers and Barriers
* H3N2 infection- Future Perspectives and Conclusion
* H3N2 infection Analyst Views
* H3N2 infection Key Companies
* Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=h3n2-infection-pipeline-appears-robust-with-15-key-pharma-companies-actively-working-in-the-therapeutics-segment-delveinsight]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/h3n2-infection-pipeline-insight
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release H3N2 Infection Pipeline Appears Robust With 15+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight here
News-ID: 4107176 • Views: …
More Releases from ABNewswire
NYC Divorce Mediation Lawyer Ryan Besinque Introduces Mediation Guidance Tailore …
New York, NY - The Law Office of Ryan Besinque, PC (https://www.besinquelaw.com/divorce-mediation-for-nyc-freelancers-and-creatives/) introduces a focused mediation resource designed for New York City freelancers and creative professionals navigating divorce. NYC divorce mediation lawyer Ryan Besinque highlights a flexible, confidential process that addresses fluctuating income, intellectual property, royalties, and goodwill while protecting long-term career interests. The initiative emphasizes collaborative valuation of creative assets and forward-looking support arrangements that reflect the realities of…
Luxenberg Garbett Kelly & George, P.C. Highlights Legal Pathways For PTSD, Anxie …
New Castle, Pennsylvania - Western Pennsylvania car accident lawyer Lawrence M. Kelly of Luxenberg Garbett Kelly & George, P.C. (https://www.lgkg.com/car-accident-psychological-injuries-ptsd-anxiety-depression/) is drawing attention to the often hidden psychological injuries that follow serious collisions, including post-traumatic stress disorder, anxiety, and depression. Backed by more than 90 years of service to injured Pennsylvanians, the firm is emphasizing that these injuries carry real medical, personal, and economic consequences that can be proven with…
Fendory Secures Disney Licensing for New On-Demand Apparel Line
United States - 02 October, 2025 - Fendory, the Print-on-Demand platform redefining licensed merchandise, has teamed up with Disney to launch a customizable apparel collection available worldwide starting today. Fans can now legally design and wear their favorite Disney characters, marking a bold step against bootlegs and toward a more creative, ethical fan experience.
The collection features iconic characters from beloved Disney franchises. Notable characters include Mickey Mouse, Minnie Mouse, Donald…
Migraine Market Growth to Surge During Forecast Period (2024-2034), Says DelveIn …
The Key Migraine Companies in the market include - Eli Lilly and Company, Teva Pharmaceuticals, Axsome Therapeutics, AEON Biopharma, Inc., Charleston Laboratories, Amgen, Teva Pharmaceuticals, Eli Lilly and Company, Anne Lindblad, Allergan, AbbVie, Tian Medical Inc., Allergan, H. Lundbeck A/S, Tonix Pharmaceuticals, Inc., Ionis Pharmaceuticals, Inc., and others.
The Migraine market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage…
More Releases for H3N2
H3N2 Infection Drugs Market Expands with New Antivirals, Monoclonal Antibodies, …
The H3N2 Infection Drugs Market is anticipated to reach, at a Significant CAGR during the forecast period 2024-2031.
The H3N2 Infection Drugs Market refers to the global industry focused on the development, production, and distribution of antiviral drugs, vaccines, and supportive therapies designed to treat and prevent H3N2 influenza infections. H3N2, a subtype of the influenza A virus, is known for causing seasonal flu outbreaks that can lead to severe complications,…
H3n2 Infection Drugs Industry Massive Growth Predicted (2024-2031)| GlaxoSmithKl …
DataM Intelligence has released a new research report on the H3n2 Infection Drugs market. The report provides a detailed analysis of current and emerging trends, offering insights into the market dynamics. It utilizes Porter's Five Forces model to assess key factors such as supplier and customer relationships, risks from various agents, competitive intensity, and opportunities for new entrants. The study also includes research data from various companies, analyzing factors like…
H3N2 Infection Treatment Market to Witness Stunning Growth | Major Giants with R …
HTF MI published the latest report, titled, "H3N2 Infection Treatment Market is Segmented by Type (Antiviral Drugs, Vaccines, Antibiotics (for secondary infections), Immunotherapy, Diagnostic Tools), Application (Hospitals, Clinics, Research Institutions, Diagnostic Labs, Pharmacies): Global Opportunity Analysis and Industry Forecast, 2024-2032". The H3N2 Infection Treatment Market has seen a market size of USD 1.8 billion in 2023 and is estimated to reach USD 3.2 billion by 2030, growth at a CAGR…
H3N2 Infection Treatment Market: Global Size, Industry Growth, Future Prospects, …
OMR recently published new report titled "H3N2 Infection Treatment Market -global trends, market share, industry size, growth, opportunities, and market forecast - 2019-2025" to its portfolio. This latest industry research study analyses the H3N2 Infection Treatment Market by different segments, companies, and regions.
Request a free sample of our report on H3N2 Infection Treatment Market: https://www.orionmarketreports.com/h3n2-infection-treatment-market/1289/#ert_pane1-1
H3N2 Infection Treatment Market research report includes the depth analysis of each segment from 2018 to…
Influenza A Virus, H3N2 Subtype Infections - Pipeline Review, H1 2017
ReportsWorldwide has announced the addition of a new report title Influenza A Virus, H3N2 Subtype Infections - Pipeline Review, H1 2017 to its growing collection of premium market research reports.
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Influenza A Virus, H3N2 Subtype Infections - Pipeline Review, H1 2017, provides an overview of the Influenza A Virus, H3N2 Subtype Infections (Infectious Disease) pipeline landscape.
H3N2 infections are caused by variant…
H3N2 Infection Market 2017 Research Report By Type, Causes, Symptoms, Precaution …
Orbis Research released a new research report of 60 pages on title “H3N2 Infection-Pipeline Insights, 2017” Report Focuses on Market, Status and Forecast, by Players, Types and Applications’ with detailed analysis, forecast and strategies.
“H3N2 Infection-Pipeline Insights, 2017”, report provides in depth insights on the pipeline drugs and their development activities around the H3N2 Infection. The Report covers the product profiles in various stages of development including Discovery, Pre-clinical, IND,…
